Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

This study has been completed.
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: June 26, 2006
Last updated: April 7, 2011
Last verified: April 2011

Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions.

The duration of the current study is 36 weeks.

Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Drug: laquinimod 0.3
Drug: laquinimod 0.6
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Reduction of brain lesions in the last 4 months of the study [ Time Frame: 36 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Relapse rate [ Time Frame: 36 weeks ] [ Designated as safety issue: No ]

Enrollment: 306
Study Start Date: March 2005
Study Completion Date: August 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Laquinimod 0.3 mg
Laquinimod 0.3 mg
Drug: laquinimod 0.3
laquinimod 0.3mg
Active Comparator: Laquinimod 0.6 mg
Laquinimod 0.6 mg
Drug: laquinimod 0.6
laquinimod 0.6mg
Placebo Comparator: Placebo
Blinded Placebo
Other: Placebo
Blinded Placebo


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Willing and able to give written informed consent
  2. Confirmed MS diagnosis as defined by the McDonald criteria
  3. R-R MS disease course.
  4. At least one gadolinium-enhanced lesion on screening MRI
  5. Women of child-bearing potential must practice a reliable method of birth control.
  6. Must understand the requirements of the study and agree to comply with the study protocol.

Exclusion Criteria:

  1. Subjects who suffer from any form of progressive MS.
  2. Any condition which the investigator feels may interfere with participation in the study.
  3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,
  4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening
  5. Previous treatment with immunomodulators within two months prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00349193

Sponsors and Collaborators
Teva Pharmaceutical Industries
Study Chair: Prof. Giancarlo Comi Teva Pharmaceutical Industries, Ltd.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ekkehard Baader, MD, Teva Pharmaceutical Europe B.V. Identifier: NCT00349193     History of Changes
Other Study ID Numbers: LAQ/5062  2004-003943-28 
Study First Received: June 26, 2006
Last Updated: April 7, 2011
Health Authority: Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ethics Committee
Poland: Ministry of Health
Russia: Pharmacological Committee, Ministry of Health
Spain: Spanish Agency of Medicines
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Teva Pharmaceutical Industries:
Relapsing Remitting Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases processed this record on October 21, 2016